United taps Ascendis to add long-acting value to treprostinil for PAH
This article was originally published in Scrip
Executive Summary
United Therapeutics has signed an exclusive agreement with Ascendis Pharma to develop yet another formulation of treprostinil, the active ingredient in United's Remodulin injection, a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH).